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The prevalence of Arbovirus (arthropod-borne virus) 
infections is increasing worldwide1. Recently, new 
clusters of autochthonous cases have been reported in 
countries with temperate climates where the competent 
vector is present2. This scenario represents a new threat 
for transfusion medicine3,4. The recent spread of Zika 
virus, new Dengue outbreaks in previously infection-
naïve areas, and the stable seasonal presence of West 
Nile virus in Europe, teach us that the risk of virus 
outbreaks is never far away5-9. 
Chikungunya virus (CHIKV) is an Arbovirus, with 
a single-stranded RNA genome, belonging to the 
Alphavirus genus of the Togaviridae family, transmitted 
to humans by the bites of infected female mosquitoes 
(Aedes aegypti and Aedes albopictus). The onset of 
symptoms (fever frequently coupled with joint and 
muscle pain, headache, nausea, fatigue and rash) usually 
occurs between 4 and 8 days after the bite of an infected 
mosquito10,11. Severe clinical complications are very 
rare and most people fully recover in 3 to 10 days12,13. 
About 85% of cases are symptomatic14, which is a higher 
proportion than for other Arbovirus infections.
CHIKV has been a significant public health concern 
in Asian and African countries, where most epidemics 
occurred in the 1960s and 1990s, and is newly emerging 
in Middle East, Pacific, American, and European 
countries4. 
Exactly 10 years after the first European outbreak of 
CHIKV, the virus has emerged again in Italy where 
the competent vector (Aedes albopictus) is present. 
The first outbreak was reported in the Emilia Romagna 
region during the summer of 20072,15,16 and involved 
the provinces of Ravenna, Forlì-Cesena, Bologna and 
Rimini, resulting in 217 confirmed out of 337 suspected 
cases. At that time, an active surveillance system 
including massive vector control actions and active case 
finding was implemented16. Laboratory investigations of 
suspected cases were performed through serology and 
in-house polymerase chain reaction analyses.  Measures 
for blood safety, in the absence of an authorised CHIKV 
test for the biological qualification of blood components, 
were based on blood donation interruption in the 
affected areas from September to October 2007 and 
on a 21-day deferral for donors who stayed, even for 
a short time, in those areas. Furthermore, the regional 
blood authority in cooperation with the National Blood 
Centre implemented an emergency blood supply plan 
in order to guarantee patients' transfusion needs in the 
Emilia-Romagna region. When the outbreak started to 
decline, the measures were gradually discontinued based 
on risk assessment results16. Blood collection restarted 
in the affected areas when the residual risk of collecting 
a viraemic donation was equal to or lower than that of 
transfusion transmitted hepatitis B virus (1:380,000, as 
estimated in Italy in 2007).
In September 2017, new autochthonous cases of 
CHIKV infection were identified in Italy. Two different 
clusters occurred in two municipalities 60 kilometres 
apart - Anzio and Rome - in the Latium region. The 
identification of CHIKV cases in Rome, among family 
members without a history of travel to endemic countries 
or to Anzio, suggested an extension of the outbreak 
through a secondary vector-borne transmission focus. 
The regional health authorities immediately started 
massive vector control measures in and around the 
affected areas, active case finding and laboratory 
investigations of suspected cases. 
Preventive blood safety measures were immediately 
introduced following a risk-benefit evaluation which 
took into account the yearly consolidated need of red 
blood cells in Latium (about 30,000 units), which is 
supplied by other Italian regions, and the fact that the 
interruption of donations in the whole municipality 
of Rome (4 million inhabitants) would have had a 
massive impact on the regional blood inventory, national 
self-sufficiency and the local health system, and that 
the spread of infection (measured as the number of 
confirmed cases) is still relatively limited.
Therefore, the following local measures were shared 
with the regional health authorities and adopted in 
Latium: (i) interruption of blood collection in the 
affected local health district of the Rome municipality 
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(1.3 million inhabitants) and in the municipality of Anzio 
(around 54,000 inhabitants); (ii) application of a 5-day 
quarantine for red blood cells collected from donors with 
a history of travel in the municipality of Anzio or in the 
affected district of Rome; (iii) reinforcement of donor 
clinical assessment; and (iv) mandatory post-donation 
information for donors who travelled in the affected 
areas and for all donors resident in the Latium region. 
Collection of plasma for fractionation is allowed as well 
as that of platelets and plasma for clinical use, provided 
pathogen inactivation is used.
The national measures are based on a 28-day deferral 
of donors who stayed, even for a short time, in the 
municipalities of Anzio and Rome, but collection of 
plasma for fractionation is allowed. Donors diagnosed 
with CHIKV infection are deferred for 4 weeks after the 
resolution of symptoms. 
At the same time, the National Blood Centre activated 
a national emergency blood supply plan, which in the 
first 10 days allowed more than 2,500 red blood cell 
units to be sent to Latium from other Italian regions. In 
addition, all regions were invited to apply the national 
guidelines for the implementation of Patient Blood 
Management17-20.
At the time of the submission of this editorial, the 
epidemiological investigation carried out by the 
regional reference laboratory for Arboviruses and the 
regional health authorities had confirmed 102 cases, 
but the investigation is still underway. Preventive blood 
safety measures will, therefore, be adapted on the basis 
of the results of the above-mentioned investigation 
and according to the geographical distribution of 
new confirmed CHIKV cases. Blood collection in 
the affected areas will gradually restart, based on the 
estimate of the residual risk of CHIKV transmission 
through blood transfusion, when available data show 
a decrease in the number of cases or as soon as a test 
for the biological qualification of blood components is 
validated and authorised.
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